neurokinin B

Ligand id: 2090

Name: neurokinin B

Species: Human, Mouse, Rat, Pig

Structure and Physico-chemical Properties

2D Structure
1. Buell G, Schulz MF, Arkinstall SJ, Maury K, Missotten M, Adami N, Talabot F, Kawashima E. (1992)
Molecular characterisation, expression and localisation of human neurokinin-3 receptor.
FEBS Lett., 299 (1): 90-5. [PMID:1312036]
2. Drapeau G, Rouissi N, Nantel F, Rhaleb NE, Tousignant C, Regoli D. (1990)
Antagonists for the neurokinin NK-3 receptor evaluated in selective receptor systems.
Regul. Pept., 31 (2): 125-35. [PMID:2176308]
3. Emonds-Alt X, Golliot F, Pointeau P, Le Fur G, Breliere JC. (1993)
Characterization of the binding sites of [3H]SR 48968, a potent nonpeptide radioligand antagonist of the neurokinin-2 receptor.
Biochem Biophys Res Commun, 191: 1172-1177. [PMID:7682062]
4. Goto Y, Hattori A, Ishii Y, Mizutani S, Tsujimoto M. (2006)
Enzymatic properties of human aminopeptidase A. Regulation of its enzymatic activity by calcium and angiotensin IV.
J. Biol. Chem., 281 (33): 23503-13. [PMID:16790432]
5. Migaud M, Durieux C, Viereck J, Soroca-Lucas E, FourniĆ©-Zaluski MC, Roques BP. (1996)
The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A.
Peptides, 17 (4): 601-7. [PMID:8804068]
6. Sarau HM, Feild JA, Ames RS, Foley JJ, Nuthulaganti P, Schmidt DB, Buckley PT, Elshourbagy NA, Brawner ME, Luttmann MA, Giardina GA, Hay DW. (2001)
Molecular and pharmacological characterization of the murine tachykinin NK(3) receptor.
Eur J Pharmacol, 413: 143-150. [PMID:11226387]
7. Sarau HM, Griswold DE, Potts W, Foley JJ, Schmidt DB, Webb EF, Martin LD, Brawner ME, Elshourbagy NA, Medhurst AD, Giardina GA, Hay DW. (1997)
Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
J Pharmacol Exp Ther, 281: 1303-1311. [PMID:9190866]
8. Zini S, Fournie-Zaluski MC, Chauvel E, Roques BP, Corvol P, Llorens-Cortes C. (1996)
Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release.
Proc. Natl. Acad. Sci. U.S.A., 93 (21): 11968-73. [PMID:8876246]